CLINICAL TRIALS PROFILE FOR VARDENAFIL HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for VARDENAFIL HYDROCHLORIDE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT00631969 ↗ | Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction | Completed | GlaxoSmithKline | Phase 3 | 2008-04-01 | This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used. |
| New Dosage | NCT00631969 ↗ | Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction | Completed | Schering-Plough | Phase 3 | 2008-04-01 | This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used. |
| New Dosage | NCT00631969 ↗ | Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction | Completed | Bayer | Phase 3 | 2008-04-01 | This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for VARDENAFIL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00377793 ↗ | Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II | Completed | Bayer | Phase 4 | 2006-07-01 | This trial is to provide additional important information on the impact of the treatment of the man its ED with vardenafil on partnership. This study is being run at up to 50 study centers in Europe and South Africa to evaluate the use of vardenafil in adult men with erectile dysfunction (often called impotence), and their female partner's sexual quality of life. Many men experience occasional erectile problems during their lives. However, when this becomes a continued problem, it can affect both the man and his female partner. The causes of erectile dysfunction are varied and may be due to physiological or emotional reasons. This study is designed to 1) study the effectiveness and safety of vardenafil, and 2) show whether treating a man its erectile dysfunction with vardenafil will improve his female partner its sexual quality of life. The second part (week 12) of the study (Educational program) a subgroup of subjects/couples, approximately 50% of the randomized subjects, will receive an educational program concerning ED in the from of a DVD. |
| NCT00379756 ↗ | A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia | Completed | GlaxoSmithKline | Phase 4 | 2006-05-22 | This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months. |
| NCT00448123 ↗ | The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients | Completed | William Beaumont Hospitals | N/A | 2007-02-01 | To determine if emergency department patients with acute ureteral colic pain due to a ureteral stone who are treated with tamsulosin, versus placebo, will experience a shorter time to passage of their stone or resolution of their pain. A secondary study objective will be to determine if there is a relationship between response to tamsulosin and stone size or position in the ureter. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VARDENAFIL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for VARDENAFIL HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for VARDENAFIL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for VARDENAFIL HYDROCHLORIDE
Sponsor Name
